MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Experiences of a personalised intervention to support self-management in PwP – PD-Care: Live Well with Parkinson’s

    T. Rookes, K. Kantilal, K. Walters, N. Kime, A. Kassavou, M. Younossi, WN. Tsang, P. Schartau, B. Gardner, N. Davies, A. Schrag (London, United Kingdom)

    Objective: 1) Evaluate acceptability and feasibility of the intervention2) Understand barriers and enablers to engagement and intervention improvement recommendations Background: We co-designed the ‘Live Well…
  • 2024 International Congress

    Spectrum of Movement disorders, Imaging findings in SSPE and response to therapy – A prospective cohort study

    A. Elavarasi, D. Dash, M. Tripathi, R. Singh, D. Vibha, A. Garg (New Delhi, India)

    Objective: We present the clinical profile, imaging, treatment trends and outcomes of a cohort SSPE patients who presented to our Institute with movement disorders. Background:…
  • 2024 International Congress

    Long-term Safety of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension

    R. Freeman, I. Biaggioni, R. Vickery, L. Norcliffe-Kaufmann, T. Guerin, M. Bryarly, V. Iodice, M. Rudzniska-Bar, M. Boczarska-Jedynak, C. Oehlwein, C. Shibao, H. Kaufmann (Boston, USA)

    Objective: To assess the long-term safety and tolerability of ampreloxetine in patients with synucleinopathies (MSA, PD, and PAF) and symptomatic neurogenic orthostatic hypotension (nOH) from…
  • 2024 International Congress

    Inter- and intra-day variability in β-Glucocerebrosidase activity and pathway biomarkers in healthy volunteers and patients with Parkinson’s disease with a GBA1 mutation

    J. Vandervalk, D. Dumas, E. Thijssen, D. Pereira, W. Grievink, Y. Yavuz, C. Pesch, D. Ysselstein, M. Hagey, J. Cedarbaum, K. Hunt, P. Kremer (Leiden, Netherlands)

    Objective: Characterize inter- and intra-day variability of β-glucocerebrosidase (GCase) activity, using a live-cell assay, and glucosyl-β sphingosine levels in healthy volunteers (HVs) and Parkinson’s disease…
  • 2024 International Congress

    The Effect of Subjective Postural Vertical on Forward Flexed Posture in Parkinson’s disease

    M. Shiraishi, K. Mikami, H. Kamo, Y. Okuma, T. Tsunemi, K. Fujimoto, T. Kamo, Y. Yokota, S. Nogawa, T. Osada, M. Seki, H. Nagayama, T. Hatano, H. Nakajima, K. Suzuki, T. Yamamoto, Y. Yamano, N. Hattori, M. Ijima (Kawasaki City, Japan)

    Objective: The present study prospectively tested the effects of the subjective postural vertical on the exacerbation of the forward flexion of trunk (FFT) through long-term…
  • 2024 International Congress

    Long-Term Safety and Efficacy of Foscarbidopa/Foslevodopa in Patients with Advanced Parkinson’s Disease: Results From an Ongoing Phase 3 Open-Label Extension with Up to 1 Year Follow-Up

    R. Hauser, V. Fung, T. Kimber, K. Klos, M. Facheris, A. Jeong, J. Jia, A. Spiegel, M. Soileau (Tampa, USA)

    Objective: Evaluate long-term safety and efficacy of foslevodopa/foscarbidopa (LDp/CDp) among people with advanced Parkinson’s disease (aPD). Background: As aPD progresses, erratic gastric emptying and pulsatile…
  • 2024 International Congress

    Effects of Mental Practice on FOG in People with Parkinson’s Disease: a Randomized Clinical Trial

    P. Silva, K. Honda, I. Nascimento, K. Nobrega, N. Pereira, T. Barolli (Sao Paulo, Brazil)

    Objective: To compare the effects of an experimental intervention (EI) based on NCI with a control intervention (CI) of equal volume and intensity, differing only…
  • 2024 International Congress

    Istradefylline effects on L-Dopa resistant tremor in Parkinson’s disease

    G. Ozay, I. Zhang, M. Umali, L. Lovelace, M. Barry, L. Ariza Serrano, A. Sharma, L. Raslan, Y. Torres-Yaghi, F. Pagan (Washington, USA)

    Objective: Quantifying Istradefylline(IST) effects in L-Dopa(LD) resistant tremor in Parkinson’s disease(PD) patients. Background: The adenosine A2A receptors control the indirect pathway. Adenosine A2A receptor activation decreases…
  • 2024 International Congress

    Unraveling Plantar Pressure Dynamics in Parkinson’s Disease with Freezing of Gait: Taking Steps through Its Characters and Predictive Factors

    T. Tiraweerakhajorn, W. Phuenpathom, P. Panyakaew, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To elucidate plantar pressure characteristics in different stages of PD patients who experienced FOG and identify predictive factors for alterations in plantar pressure parameters.…
  • 2024 International Congress

    Adaptive vs Conventional Chronic Deep Brain Stimulation: Results from a Randomized Pilot Trial in Parkinson’s Disease

    I. Isaias, S. Marceglia, L. Romito, R. Eleopra, L. Borellini, V. Levi, M. Locatelli, T. Mandat, E. Pirola, A. Ampollini, M. Lanotte, L. Lopiano, M. Zibetti, A. Bentivoglio, C. Piano, A. Izzo, F. Tamma, G. Foffani, A. Lozano, E. Moro, J. Volkmann, C. Conti, M. Arlotti, L. Krinke, L. Rossi, A. Priori (Milan, Italy)

    Objective: To assess the safety and efficacy of chronic adaptive (aDBS) and conventional (cDBS) deep brain stimulation of the subthalamic nucleus in patients with Parkinson’s…
  • « Previous Page
  • 1
  • …
  • 99
  • 100
  • 101
  • 102
  • 103
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley